IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 348 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $338,250 | -2.1% | 7,457 | -11.4% | 0.20% | 0.0% |
| Q2 2023 | $345,391 | +20.1% | 8,418 | +4.6% | 0.20% | +29.7% |
| Q1 2023 | $287,493 | -3.6% | 8,044 | +1.8% | 0.16% | +1.3% |
| Q4 2022 | $298,383 | -4.1% | 7,900 | +12.4% | 0.16% | +25.8% |
| Q3 2022 | $311,000 | +21.5% | 7,029 | +1.5% | 0.12% | +30.5% |
| Q2 2022 | $256,000 | -43.7% | 6,925 | -43.7% | 0.10% | -53.4% |
| Q1 2022 | $455,000 | +21.7% | 12,296 | 0.0% | 0.20% | +44.7% |
| Q4 2021 | $374,000 | -7.9% | 12,296 | +1.6% | 0.14% | -21.2% |
| Q3 2021 | $406,000 | -23.0% | 12,102 | -8.4% | 0.18% | -17.5% |
| Q2 2021 | $527,000 | -10.4% | 13,212 | +1.0% | 0.22% | -12.5% |
| Q1 2021 | $588,000 | -18.2% | 13,084 | +2.8% | 0.25% | -16.8% |
| Q4 2020 | $719,000 | +51.4% | 12,725 | +27.1% | 0.30% | +19.7% |
| Q3 2020 | $475,000 | -12.2% | 10,013 | +9.2% | 0.25% | -2.7% |
| Q2 2020 | $541,000 | +22.7% | 9,170 | -1.7% | 0.26% | +41.4% |
| Q1 2020 | $441,000 | -27.8% | 9,329 | -7.8% | 0.18% | +81.0% |
| Q4 2019 | $611,000 | -8.5% | 10,116 | -9.3% | 0.10% | -25.9% |
| Q3 2019 | $668,000 | -20.3% | 11,156 | -14.4% | 0.14% | -23.7% |
| Q2 2019 | $838,000 | +36.3% | 13,037 | +14.7% | 0.18% | +68.6% |
| Q4 2018 | $615,000 | -27.9% | 11,369 | -31.2% | 0.10% | +19.3% |
| Q3 2018 | $853,000 | +32.9% | 16,532 | +7.2% | 0.09% | -84.5% |
| Q2 2018 | $642,000 | -17.2% | 15,418 | -12.3% | 0.57% | -15.5% |
| Q1 2018 | $775,000 | -17.2% | 17,582 | -5.5% | 0.67% | -42.8% |
| Q4 2017 | $936,000 | -9.4% | 18,610 | -8.7% | 1.18% | +745.3% |
| Q3 2017 | $1,033,000 | -0.3% | 20,375 | 0.0% | 0.14% | -10.3% |
| Q2 2017 | $1,036,000 | +17.7% | 20,375 | -6.9% | 0.16% | -1.3% |
| Q1 2017 | $880,000 | -7.0% | 21,881 | +10.6% | 0.16% | -44.5% |
| Q4 2016 | $946,000 | -7.3% | 19,777 | -29.0% | 0.28% | -42.7% |
| Q3 2016 | $1,021,000 | +80.1% | 27,856 | +14.4% | 0.49% | +17.3% |
| Q2 2016 | $567,000 | +34.0% | 24,345 | +133.0% | 0.42% | -27.8% |
| Q1 2016 | $423,000 | -34.6% | 10,447 | 0.0% | 0.58% | -67.2% |
| Q4 2015 | $647,000 | – | 10,447 | – | 1.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |